The White House expanded its most-favored-nation (MFN) Medicaid pricing framework, adding nine midsized drugmakers to agreements that aim to align Medicaid pricing with those in peer countries. Reporting indicates the new entrants include a mix of branded and specialty-focused companies, bringing the initiative’s coverage broader beyond only the largest manufacturers. The policy’s near-term effect on revenues appears limited for drugmakers, but the administration’s growing participation raises questions for biotech partners and suppliers tied to downstream payer coverage and formulary placement. Industry focus remains on whether companies comply without triggering tariff exposure or Medicare pilot-program inclusion. Separately, new access data from IQVIA suggests that negotiated Medicare “maximum fair price” plans do not guarantee patient access. Initial claim rejections remained elevated after January 1, 2026 implementation for the first set of negotiated drugs, with especially high rejection rates in immunology and oncology. Together, the announcements spotlight two operational realities for biopharma: policy-driven price alignment is expanding, while utilization management mechanisms (prior authorization and step therapy) continue to shape whether patients can obtain therapies at the point of care.